Global Active Pharmaceutical Ingredient Market Size, Share, Growth & Trends Analysis Report By Type (Synthetic Chemical API, Biotech/Biological API, Plant Extracts API, High-potency API, Classical Fermentation API) By Therapeutic (Anti-infective Drugs, Metabolic Disorders Drugs, Cardiovascular Drugs, Oncology Drugs, Central Nervous System Drugs, Respiratory Diseases Drugs, others) And Regional Market Intelligence & Forecast, 2019-2026.
Date: Jul-2019 | Id: MACRC-0017 | Geographical Scope: Global | Publisher: MACRC
Introduction
Active Pharmaceutical Ingredient is defined as the elements which are used in the formulation of a finished or final pharmaceutical product (FPP), which intends to effect directly in the diagnosis, cure, treatment, prevention of diseases or also can change physiological functions in human beings.
The demand for active pharmaceutical ingredients is increasing due to the drastic growth of acute and chronic diseases. The total market for Active Pharmaceutical Ingredients estimated at US$ 17.3 Billion in 2019 and projected to grow 25.7 Billion by 2026 with a CAGR of 6.2% from 2019 to 2026. The tremendous growth of the Active Pharmaceutical Ingredient market is due to the usage of biological drugs for the treatment of diseases, and also the growing importance of generics. Following the guidelines of the International Conference on Harmonisation (ICH), Good Manufacturing Practices (GMP) and also Current GMP (cGMP) the standards of safety has been increasing. The API market is also facing challenges from the manufacturing of the drug within a time technique for reducing the cost of manufacturing and maintaining the quality and safety of the drug without leveraging on the profit.
Though the APIs market is dominated by anti-invectives, diabetics, cardiovascular analgesics, cancer, and many other aided diseases. such as usage in novel formulations targeting therapeutic areas. Availability of skilled workforce and limited accessibility of drugs in the developing countries and the increasing penetration of counterfeit drugs are expected to hold the growth of API market in the coming years.
Market Segmentation
The Active Pharmaceutical Ingredients Market is segmented into API type, drug type, therapy area, manufactures and geography. On the basis of applications, the drug segment is expected to hold the largest market share in 2019. The API type market is segmented into biological and chemical APIs. The drug type is segmented into generic, over-the-counter (OTC) and innovative drugs. Based on the therapy area the market is segmented into Oncology drugs, Non-Steroidal Anti-Inflammatory drugs, Anti-Diabetic drugs, Neurology drugs, cardiovascular drugs, and others. Based on manufactures the market is segmented into captive or In-house manufacturer and Merchant or Contract manufacturers. The Captive API manufactures hold the highest market share in the API.
Region-wise, North America Market holds the highest market share expected to continue throughout the forecasted period. The majority of its API requirements are through the imports from the Asian Markets. Nearly 80 to 85% of the APIs imported to the USA are from India and China.
Market Trends
National Cancer Institute of USA has developed drugs for the treatment of cancer and which has been approved by the FDA. The drugs approved are for anal cancer, Bladder cancer, Brain tumors, Breast cancer, cervical cancer, etc. Astellas Pharma INC., Celgene Corporation, Johnson &Johnson, MERCK &Co. , Novartis AG, are some of the key players in the oncology drugs market which are manufacturing Rituximab, Trastuzumab, Bevacizumab, and many more APIs.
The competitive profiling of key players of APIs management market includes company and financial overview, and their recent developments, and products offered by them which helps in assessing competition within the market. Teva Pharmaceutical Industries Ltd. Is a major key producer of generic medicines and a recognized player in innovative and specialty pharmaceuticals around the World.
Key questions addressed by the report:
- What are the Global Market Size for the API market and Growth rate from 2019 to 2026?
- How is the API market segmented?
- What are the supporting factors which are driving the growth of the market?
- Who are the key players in the oncology drugs market?
Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions 1.3. List of Data Sources 1.4. List of Abbreviations Chapter 2. Executive Summary 2.1. Active Pharmaceutical Ingredient Market - Industry Snapshot 2.2. Active Pharmaceutical Ingredient Market Chapter 3. Active Pharmaceutical Ingredient Market Outlook 3.1. Market Segmentation 3.2. Value Chain Analysis 3.3. Market Dynamics 3.3.1. Market driver analysis 3.3.2. Market restraint analysis 3.3.3. Market opportunity analysis 3.4. Penetration & Growth Prospects Mapping 3.5. Industry Analysis - Porter’s Five Forces Analysis 3.6. PESTEL Analysis Chapter 4. Active Pharmaceutical Ingredient Market: By Type of APIs (USD Billion) 4.1. Synthetic Chemical API 4.2 Biotech/Biological API 4.3. Plant Extracts API 4.4. High-potency API 4.5. Clasical Fermentation API Chapter 5. Active Pharmaceutical Ingredient Market: Therapeutic (USD Billion) 5.1 Anti-infective Drugs 5.2 Metabolic Disorders Drugs 5.3 Cardiovascular Drugs 5.4 Oncology Drugs 5.5 Central Nervous System Drugs 5.6 Respiratory Diseases Drugs 5.7 Others Chapter 6. Active Pharmaceutical Ingredient Market: Regional Outlook 6.1. Active Pharmaceutical Ingredient Market Estimates & Forecasts 6.2. North America 6.2.1. Market estimates and forecasts 6.2.2. Market estimates and forecasts, By Type of APIs 6.2.3. Market estimates and forecasts, By Therapeutic 6.2.4. U.S. 6.2.4.1. Market estimates and forecasts 6.2.4.2. Market estimates and forecasts, By Type of APIs 6.2.4.3. Market estimates and forecasts, By Therapeutic 6.2.5. Canada 6.2.5.1. Market estimates and forecasts 6.2.5.2. Market estimates and forecasts, By Type of APIs 6.2.5.3. Market estimates and forecasts, By Therapeutic 6.3. Europe 6.3.1. Market estimates and forecasts 6.3.2. Market estimates and forecasts, By Type of APIs 6.3.3. Market estimates and forecasts, By Therapeutic 6.3.4. U.K. 6.3.4.1. Market estimates and forecasts 6.3.4.2. Market estimates and forecasts, By Type of APIs 6.3.4.3. Market estimates and forecasts, By Therapeutic 6.3.5. Germany 6.3.5.1. Market estimates and forecasts 6.3.5.2. Market estimates and forecasts, By Type of APIs 6.3.5.3. Market estimates and forecasts, By Therapeutic 6.3.6. France 6.3.6.1. Market estimates and forecasts 6.3.6.2. Market estimates and forecasts, By Type of APIs 6.3.6.3. Market estimates and forecasts, By Therapeutic 6.4. Asia Pacific 6.4.1. Market estimates and forecasts 6.4.2. Market estimates and forecasts, By Type of APIs 6.4.3. Market estimates and forecasts, By Therapeutic 6.4.4. China 6.4.4.1. Market estimates and forecasts 6.4.4.2. Market estimates and forecasts, By Type of APIs 6.4.4.3. Market estimates and forecasts, By Therapeutic 6.4.5. India 6.4.5.1. Market estimates and forecasts 6.4.5.2. Market estimates and forecasts, By Type of APIs 6.4.5.3. Market estimates and forecasts, By Therapeutic 6.4.6. Japan 6.4.6.1. Market estimates and forecasts 6.4.6.2. Market estimates and forecasts, By Type of APIs 6.4.6.3. Market estimates and forecasts, By Therapeutic 6.4.7. Singapore 6.4.7.1. Market estimates and forecasts 6.4.7.2. Market estimates and forecasts, By Type of APIs 6.4.7.3. Market estimates and forecasts, By Therapeutic 6.5. Latin America 6.5.1. Market estimates and forecasts 6.5.2. Market estimates and forecasts, By Type of APIs 6.5.3. Market estimates and forecasts, By Therapeutic 6.5.4. Brazil 6.5.4.1. Market estimates and forecasts 6.5.4.2. Market estimates and forecasts, By Type of APIs 6.5.4.3. Market estimates and forecasts, By Therapeutic 6.5.5. Mexico 6.5.5.1. Market estimates and forecasts 6.5.5.2. Market estimates and forecasts, By Type of APIs 6.5.5.3. Market estimates and forecasts, By Therapeutic 6.6. Middle East & Africa 6.6.1. Market estimates and forecasts 6.6.2. Market estimates and forecasts, By Type of APIs 6.6.3. Market estimates and forecasts, By Therapeutic Chapter 7. Competitive Landscape 7.1. Teva Pharmaceutical Industries Ltd. 7.1.1. Company overview 7.1.2. Financial performance 7.1.3. Product benchmarking 7.1.4. Recent developments 7.2. Sun Pharmaceutical Industries Ltd 7.2.1. Company overview 7.2.2. Financial performance 7.2.3. Product benchmarking 7.2.4. Recent developments 7.3. Aurobindo Pharma 7.3.1. Company overview 7.3.2. Financial performance 7.3.3. Product benchmarking 7.3.4. Recent developments 7.4. Pfizer Inc. 7.4.1. Company overview 7.4.2. Financial performance 7.4.3. Product benchmarking 7.4.4. Recent developments 7.5. Boehringer Ingelheim International GmbH 7.5.1. Company overview 7.5.2. Financial performance 7.5.3. Product benchmarking 7.5.4. Recent developments 7.6. Merck & Co., Inc. 7.6.1. Company overview 7.6.2. Financial performance 7.6.3. Product benchmarking 7.6.4. Recent developments 7.7. Novartis AG 7.7.1. Company overview 7.7.2. Financial performance 7.7.3. Product benchmarking 7.7.4. Recent developments 7.8. F. Hoffmann-La Roche Ltd. 7.8.1. Company overview 7.8.2. Financial performance 7.8.3. Product benchmarking 7.8.4. Recent developments 7.9. Bayer AG 7.9.1. Company overview 7.9.2. Financial performance 7.9.3. Product benchmarking 7.9.4. Recent developments 7.10. Sanofi 7.10.1. Company overview 7.10.2. Financial performance 7.10.3. Product benchmarking 7.10.4. Recent developments
Related reports
Non-Hodgkin Lymphoma Therapeutics Market
$2000-$6000
Acrylic Teeth Market
$3600-$7000